AZD5423

Systematic (IUPAC) name
	2,2,2-Trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide
Identifiers
ChemSpider	28536140
Chemical data
Formula	C25H21F4N3O3
Molecular mass	487.446 g/mol
	SMILES C[C@@H]([C@@H](c1cccc(c1)OC)Oc2ccc3c(c2)cnn3c4ccc(cc4)F)NC(=O)C(F)(F)F ;
	InChI InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1 ; Key:FCNQMDSJHADDFT-WNSKOXEYSA-N ;

Lua error in package.lua at line 80: module 'strict' not found.

AZD5423 is a nonsteroidal glucocorticoid and phase II drug by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.^[1]^[2]^[3]^[4]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.